PLGA: A unique polymer for drug delivery

Therapeutic Delivery

Volumn 6, Issue 1, 2015, Pages 41-58

  Kapoor, Deepak N ^a   Bhatia, Amit ^a   Kaur, Ripandeep ^a   Sharma, Ruchi ^a   Kaur, Gurvinder ^a   Dhawan, Sanju ^a,b  

^a LOVELY PROFESSIONAL UNIVERSITY   (India)

^b DR REDDY'S LABORATORIES LTD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

COSMETIC; NANOPARTICLE; POLYGLACTIN; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

BIOCOMPATIBILITY; BIODEGRADABILITY; BIODEGRADATION; CARDIOVASCULAR DISEASE; CHEMICAL COMPOSITION; COACERVATION; CRYSTALLIZATION; DENTISTRY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG TARGETING; EVAPORATION; GLASS TRANSITION TEMPERATURE; HUMAN; HYDROPHILICITY; MOLECULAR WEIGHT; NANOFABRICATION; NONHUMAN; ORTHOPEDICS; PARTICLE SIZE; PH; PHASE SEPARATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SPRAY DRYING; SUSTAINED DRUG RELEASE; SYNTHESIS; TISSUE ENGINEERING; TRANSDERMAL DRUG ADMINISTRATION; BIOREMEDIATION; CHEMISTRY;

BIODEGRADATION, ENVIRONMENTAL; DRUG DELIVERY SYSTEMS; LACTIC ACID; NANOPARTICLES; POLYGLYCOLIC ACID;

EID: 84920719388     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.14.91     Document Type: Review

References (132)

1. Biondi M, Ungaro F, Quaglia F, Netti P. Controlled drug delivery in tissue engineering. Adv. Drug Del. Rev. 60(2), 229-242 (2008).
2. Thakral S, Thakral N, Majumdar D. Eudragit: a technology evaluation. Expert Opin. Drug Deliv. 10(1), 131-149 (2013).
3. Doctor H. Evaluation of various prosthetic material and newer meshes for hernia repairs. J. Minim. Access Surg. 2(3), 110-116 (2006).
4. Acton A. Siloxanes-Advances in Research and Application. Scholarly Editions, Atlanta, Georgia (2013).
5. Deshpande A, Heller J, Gurny R. Bioerodible polymers for ocular drug delivery. Crit. Rev. Ther. Drug Care Syst. 15 (4), 381-420 (1998).
6. Astete C, Sabliov C. Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polym. Ed. 17(3), 247-289 (2006).
7. Ratner B, Horbelt T, Hoffman A, Mallschka S. Cell adhesion to polymeric materials: implication with respect to biocompatibility. J. Biomed. Mater. Res. 9, 407-423 (1975).
8. Khatri K, Goyal A, Vyas S. Potential of nanocarriers in genetic immunization. Recent Pat. Drug Deliv. Formul. 2(1), 68-82 (2008).
9. Postlethwait R. Poly(glycolic acid) surgical suture. Arch. Surg. 101, 489-494 (1970).
10. Horton C. Vicryl synthetic absorbable sutures. Am. J. Surg. 40, 729-731 (1974).
11. Benicewicz B, Oser Z, Clemow A, Shalaby S. Artifcial absorbable ligament or tendon prostheses containing lactide or glycolide-lactide polymeric fbers. European Patent Application 302, 979, (1987).
12. Benicewicz B, Shalaby S, Clemow A, Oser Z. In vitro and in vivo degradation of poly(l-lactide) braided multiflament yarns. In: Agriculture and Synthetic Polymers, Glass Je, Swift G (Eds). American Chemical Society, Washington DC, USA, Chapter 14 (1990).
13. Hwang N, Varghese S, Elisseeff J. Controlled differentiation of stem cells. Adv. Drug Del. Rev. 60(2), 199-214 (2008).
14. Ballestrero A, Boy D, Moran E, Cirmena G, Brossart P, Nencioni A. Immunotherapy with dendritic cells for cancer. Adv. Drug Deliv. Rev. 60(2), 173-183 (2008).
15. Chaubal M. Polylactides/glycolides-excipients for injectable drug delivery and beyond. Drug Deliv. Tech. 2, 34-36 (2002).
16. Gupta A, Kumar V. New emerging trends in synthetic biodegradable polymers-polylactide: a critique. Eur. Polymer J. 43, 4053-4074 (2007).
17. Lewis D. Controlled release of bioactive agents from lactide/glycolide polymers In: Biodegradable Polymers as Drug Delivery Systems, Chasin M, Langer R (Eds). Marcel Dekker, New York, USA (1990).
18. Berkland C, Pollauf E, Pack D, Kim K. Uniform double-walled polymer microspheres of controllable shell thickness. J. Cont. Rel. 96, 101-111 (2004).
19. Wako: Biodegradable Polymers (PLA. PLGA) (October 2010), (2010).
20. Durect. Lactel Absorbable Polymers: poly(D, L-lactide-co-glycolide) www.absorbables.com.
21. Wu L, Zhang J, Jing D, Ding J. Wet state mechanical properties of three dimensional polyester porous scaffolds. J. Biomed. Mater. Res. A. 76, 264-271 (2006).
22. Graham P, Brodbeck K, Mchugh A. Phase inversion dynamics of PLGA solutions related to drug delivery. J. Cont. Rel. 58, 233-245 (1999).
23. Lamprecht A, Ubrich N, Perez M, Lehr C, Hoffman M, Maincent P. Infuences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique. Int. J. Pharm. 196, 177-182 (2000).
24. Park T. Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition. Biomaterials 16, 1123-1130 (1995).
25. Makadia H, Siegel S. Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 3, 1377-1397 (2011).
26. Lu J, Wang X, Muller M et al. Current advances in research and clinical applications of PLGA based nanotechnology 4(9), 325-341 (2009).
27. Wu H, Gopal J, Abdelhamid H, Hasan N. Quantum dot applications endowing novelty to analytical proteomics. 12(19-20), 2949-2961 (2012).
28. Cong L, Wissner-Gross A. Interrogating single molecules. Recent Pat. Nanotechnol. 2(1), 19-24 (2008).
29. Ranade V. Drug delivery systems: 3A. Role of polymers in drug delivery. J. Clin. Pharmacol. 30, 10-23 (1990).
30. Estey T, Kang J, Schwendeman S, Carpenter J. BSA degradation under acidic conditions: a model for protein instability during release from PLGA delivery systems. J. Pharm. Sci. 95(7), 1626-1639 (2006).
31. Leemhuis M, Kruijtzer J, Nostrum C, Hennink W. In vitro hydrolytic degradation of hydroxyl-functionalized poly(r-hydroxy acid)s. Biomacromolecules 8, 2943-2949 (2007).
32. Heller J. Fundamentals of polymer science. In: Controlled Drug Delivery: Fundamentals and Applications, Robinson Jr. Lee Vhl (Eds). Marcel Dekker, New York, USA 139-212 (1987).
33. Luan X, Bodmeier R. Infuence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems. J. Cont. Rel. 110(2), 266-272 (2006).
34. Dong W, Körber M, López Esguerra V, Bodmeier R. Stability of poly(d, l-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems. J. Cont. Rel. 115(2), 158-167 (2006).
35. Tsuji H, Mizuno A, Ikada Y. Properties and morphology of poly(L-lactide). III. Effects of initial crystallinity on long-term in vitro hydrolysis of high molecular weight poly(L-lactide) flm in phosphate-buffered solution. J. Appl. Polym. Sci. 77, 1452-1464 (2000).
36. Schliecker G, Schmidt C, Fuchs S, Wombacher R, Kissel T. Hydrolytic degradation of poly(lactide-co-glycolide) flms: effect of oligomers on degradation rate and crystallinity. Int. J. Pharm. 266, 39-49 (2003).
37. Park T. Degradation of poly (D, L-lactic acid) microspheres: effect of molecular weight. J. Cont. Rel. 30(2), 161-173 (1994).
38. Liggins R. Paclitaxel loaded poly(L-lactic acid) microspheres: properties of microspheres made with low molecular weight polymers. Int. J. Pharm. 222, 19-33 (2001).
39. Holy C. In vitro degradation of a novel poly(lactide-co-glycolide) 75/25 foam. Biomaterials 20, 1177-1185 (1999).
40. Zolnik B, Burgess D. Effect of acidic pH on PLGA microsphere degradation and release. J. Cont. Rel. 122, 338-344 (2007).
41. Frank A, Rath S, Venkatraman S. Controlled release from bioerodible polymers: effect of drug type and polymer composition. J. Cont. Rel. 102, 333-344 (2005).
42. Siegel S, Kahn J, Metzger K, Winey K, Werner K, Dan N. Effect of drug type on the degradation rate of PLGA matrices. Eur. J. Pharm. Biopharm. 64, 287-293 (2006).
43. Grizzi I, Garreau H, Li S, Vert M. Hydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence. Biomaterials 16, 305-311 (1995).
44. Witt C. Morphological characterization of microspheres, flms and implants prepared from poly(lactide-co-glycolide) and ABA triblock copolymers: is the erosion controlled by degradation, swelling or diffusion. Eur. J. Pharm. Biopharm. 51, 171-181 (2001).
45. Eniola A, Hammer D. Characterization of biodegradable drug delivery vehicles with the adhesive properties of leukocytes II. Effect of degradation on targeting activity. Biomaterials 26, 661-670 (2005).
46. Jain A, Gulbake A, Shilpi S, Hurkat P, Jain S. Peptide and protein delivery using new drug delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 30(4), 293-329 (2013).
47. Houchin M, Topp E. Chemical degradation of peptides and proteins in PLGA. A review of reactions and mechanisms. J. Pharm. Sci. 97, 2395-2404 (2008).
48. Mahapatro A, Singh D. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J. Nanobiotech. 9, 55-66 (2011).
49. Moghimis M, Hunter A, Murray J. Nanomedicine: current status and future prospects. FASEB J. 19 (3), 311-330 (2005).
50. Thompson M. A tremendous research opportunity for analytical chemists. Analyst 129, 671-685 (2004).
51. Kumari A, Yadav S, Yadav S. Biodegradable polymeric nanoparticles based drug delivery systems. Coll. Surf B Interfaces. 75, 1-18 (2010).
52. Zambaux M, Bonneaux F, Gref R et al. Infuence of experimental parameters on the chararcteristics of poly (lactic acid) nanoparticles prepared by double emulsion method. J. Control. Release 50, 31-40 (1998).
53. Stevanovic M, Ignjatovic N, Jordovic B, Uskokovic D. Stereological analysis of the poly (DL lactide-co glycolide) submicron sphere prepared by solvent/non solvent chemical methods and centrifugal processing. J. Mater. Sci. Mater. Med. 18(7), 1339-1344 (2007).
54. Niwa T, Takeuchi H, Hinto T, Kunou N, Kawashima Y. Preparation of biodegradable nanoparticles of water soluble and insoluble drugs with DL lactide/glycolide copolymer by a novel spontaneous emulsifcation solvent diffusion method and the drug release behaviour. J. Cont. Rel. 25, 89-98 (1993).
55. Arshady R. Preparation of biodegradable microspheres and microcapsules: 2.polyactides and related polyesters. J. Cont. Rel. 17, 1-21 (1991).
56. Chaisri W, Hennink W, Okonogi S. Preparation and characterization of cephalexin loaded PLGA microspheres. Curr. Drug Deliv. 6, 69-75 (2009).
57. Maos, Xu J, Cai C, Germershaus O, Schaper A, Kissel T. Effect of wow process parameters onmorphology and burst release of FTIC dextran loaded PLGA microspheres. Int. J. Pharm. 334, 137-148 (2007).
58. Thomasin C, Merkle H, Gander B. Drug microencapsulation by PLA/PLGA coacervation in the light of thermodynamics. Parameters determining microsphere formation. J. Pharm. Sci. 87, 269-275 (1998).
59. Edelman R, Russell R, Losonsky G et al. Immunization of rabbits with enterotoxigenic E. Coli colonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide). Vaccine 11, 155-158 (1993).
60. Hua F, Park T, Lee D. A facile preparation of highly interconnected macroporous poly(D, Llactic acid-co-glycolic acid) (PLGA) scaffolds by liquid-liquid phase separation of a PLGAdioxane-water ternary system. Polymer 44, 1911-1920 (2003).
61. Mu L, Feng S. Fabrication, characterization and in vitro release of paclitaxel (Taxol® ) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifers. J. Cont. Rel. 76, 239-254 (2001).
62. Gavini E, Chetoni P, Cossu M, Alvarez M, Saettone M, Giunchedi P. PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsifcation/spray-drying as the preparation method: In vitro/in vivo studies. Eur. J. Pharm. Biopharm. 57, 207-212 (2004).
63. Nie H, Lee L, Tong H, Wang C. PLGA/chitosan composites from a combination of spray drying and supercritical fuid foaming techniques: new carriers for DNA delivery. J. Cont. Rel. 129, 207-214 (2008).
64. Wagenaar B, Muller B. Piroxicam release from spray-dried biodegradable microspheres. Biomaterials 15, 49-54 (1994).
65. Castelli F, Conti B, Conte U, Puglisi G. Effect of molecular weight and storage times on tolmetin release from poly-lactide microspheres to lipid model membrane. A calorimetric study. J. Cont. Rel. 40, 277-284 (1996).
66. Loscertales I, Barrero A, Guerrero I, Cortijo R, Marquez M, Ganan-Calvo A. Micro/Nano encapsulation via electrifed coaxial liquid jets. Science 295, 1695-1698 (2002).
67. Christoper G, Raghavan C, Siddharth K, Kumar M, Prasad R. Formulation and optimization of coated PLGA-Zidovudine nanoparticles using factorial design and in vitro in vivo evaluations to determine brain targeting effciency. Saudi Pharm. J. (2013) (In Press).
68. Moghimi S, Hunter A, Murray J. Nanomedicine: current status and future prospects. FASEB J. 19(3), 311-330 (2005).
69. Hans M, Lowman A. Biodegradable nanoparticles for drug delivery and targeting. Solid State Mater. Sci. 6, 319-327 (2002).
70. Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Preparation of poly(D, L-lactide-coglycolide) nanoparticles by modifed spontaneous emulsifcation solvent diffusion method. Int. J. Pharm. 187, 143-152 (1999).
71. Konan Y, Cerny R, Favet J, Berton M, Gurny R, Allemann E. Preparation and characterization of sterile sub-200 nm meso-tetra(4-hydroxylphenyl)porphyrin-loaded nanoparticles for photodynamic therapy. Eur. J. Pharm. Biopharm. 55, 115-124 (2003).
72. Tom J, Debenedetti P. Particle formation with superritical fuids-A review. J. Aerosol. Sci. 22, 555-584 (1991).
73. Randolph T, Randolph A, Mebes M, Yeung S. Submicron sized biodegradable particles of poly (L-lactic acid) via the gas antisolvent spray precipitation process. Biotechnol. 9, 429-435 (1993).
74. Mishima K, Matsuryama K, Tanabe D, Yamauchi S. Microencapsulation of proteins by rapid expansion of supercritical solution with a non solvent. AIChE J. 46, 857-865 (2000).
75. Koushik K, Kompella U. Preparation of large porous Deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process. Pharm. Res. 21, 524-535 (2004).
76. Davies O, Lewis A, Whitaker M, Tai H, Shakesheff K, Howdle S. Applications of supercritical CO2 in the fabrication of polymer systems for drug delivery and tissue engineering. Adv. Drug Del. Rev. 60(3), 373-387 (2008).
77. Hile D, Amirpour M, Akgerman A, Pishko M. Active growth factor delivery from poly (D, L-lactide-co-glycolide) foams prepared in supercritical CO2. J. Cont. Rel. 66, 177-185 (2000).
78. Rabin C, Liang Y, Ehrlichman R et al. In vitro and in vivo demonstration of risperidone implants in mice. Schizophr Res. 98, 66-78 (2008).
79. Widmer M. Manufacture of porous biodegradable polymer conduits by an extrusion process for guided tissue regeneration. Biomaterials 19, 1945-1955 (1998).
80. Wang C, Wang W, Meyer R, Liang Y, Winey K, Siegel S. A rapid method for creating drug implants: translating laboratory-based methods into a scalable manufacturing process. J. Biomed. Mater. Res. Part B Appl. Biomater. 93, 562-572 (2010).
81. Alarcon C, Pennadam S, Alexander C. Stimuli responsive polymers for biomedical applications. Chem. Soc. Rev. 34, 276-285 (2005).
82. Sah H. Protein behaviour at the water methylene chloride interface. J. Pharm. Sci. 88, 1320-1325 (1999).
83. Veronese F. Peptide and protein pegylation: a review of problems and solutions. Biomaterials 22, 405-417 (2001).
84. Vasita R, Mani G, Aggarwal M, Katti D. Degradation behavior of electrospun microfbres of blends of poly (lactide-co-glycolide) and pluronic F-108. Polymer Degradation Stability 95, 1605-1613 (2010).
85. Paillard-Giteau A, Tran V, Thomas O et al. Effect of various additives and polymers on lysozyme release from PLGA microspheres prepared by an s/o/w emulsion technique. Eur. J. Pharma. Biopharm. 75, 128-136 (2010).
86. Mundargi R, Babu V, Rangaswamy V, Patel P, Aminabhavi T. Nano/micro technologies for delivering macromolecular therapeutics using poly(d, l-lactide-co-glycolide) and its derivatives. J. Cont. Rel. 125(3), 193-209 (2008).
87. Samati Y, Yuksel N, Tarimci N. Preparation and characterization of poly(D, L-lactic-co-glycolic acid) microspheres containing furbiprofen sodium. Drug Del. 13, 105-111 (2005).
88. Chaudhari K, Kumar A, Khandelwal V et al. Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel. J. Cont. Rel. 158 470-478 (2012).
89. Gaignauxa A, Reeffa J, Siepmannb F et al. Development and evaluation of sustained-release clonidine-loaded PLGA microparticles Int. J. Pharm. 437, 20-28 (2012).
90. Reyes R, Riva B, Delgado A, Hernandez A, Sanchez E, Evora C. Effect of triple growth factor controlled delivery by a brushite-PLGA system on a bone defect Int. J. Care Injured 43, 334-342 (2012).
91. Ozekia T, Kaneko D, Hashizawa K, Imai Y, Tagami T, Okada H. Improvement of survival in C6 rat glioma model by a sustained drug release from localized PLGA microspheres in a thermoreversible hydrogel Int. J. Pharm. 427 299-304 (2012).
92. Jung M, Shim I, Chung H et al. Local BMP-7 release from a PLGA scaffolding-matrix for the repair of osteochondral defects in rabbits J. Cont. Rel. 162, 485-491 (2012).
93. Van De Vena H, Vermeersch M, Matheeussen A et al. PLGA nanoparticles loaded with the antileishmanial saponin β-aes' in vitro effcacy evaluation Int. J. Pharm. 420, 122-132 (2011).
94. Wiebera A, Selzera T, Kreuter J. Characterisation and stability studies of a hydrophilic decapeptide in different adjuvant drug delivery systems: a comparative study of PLGA nanoparticles versus chitosan-dextran sulphate microparticles versus DOTAP-liposomes. Int. J. Pharm. 421, 151-159 (2011).
95. Ungaro F, Angelo I, Coletta C et al. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation effciency, release rate and lung deposition pattern by hydrophilic polymers J. Cont. Rel. 157, 149-159 (2012).
96. Cole A, David A, Wang J, Galbán C, Yang V. Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modifed, cross-linked starch-coated iron oxide nanoparticles. Biomaterials 32(26), 6291-6301 (2011).
97. Lanao R, Leeuwenburgh S, Wolke J, Jansen J. In vitro degradation rate of apatitic calcium phosphate cement with incorporated PLGA microspheres Acta Biomat. 7, 3459-3468 (2011).
98. Parveen S, Sahoo S. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Eur. J. Pharmacol. 670, 372-383 (2011).
99. Chang-Lin J, Attar M, Acheampong A et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest. Oph. Vis. Sci. 52(1), 80-86 (2011).
100. Steele T, Huang C, Widjaja E, Boey F, Loo J, Venkatraman S. The effect of polyethylene glycol structure on paclitaxel drug release and mechanical properties of PLGA thin flms. Acta Biomaterialia 7, 1973-1983 (2011).
101. Sendil D, Bonney I, Carr D, Lipkowski A, Wise D, Hasirci V. Antinociceptive effects of hydromorphone, bupivacaine and biphalin released from PLGA polymer after intrathecal implantation in rats Biomaterials 24, 1969-1976 (2003).
102. Fredriksen B, Sævareid K, Mcauley L, Lane M, Bgwald J, Dalmo R. Early immune responses in Atlantic salmon (Salmo salar L.) after immunization with PLGA nanoparticles loaded with a model antigen and β-glucan. Vaccine 29, 8338-8349 (2011).
103. Chakravarthi S, Robinson D. Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles. Int. J. Pharm. 409, 111-120 (2011).
104. Andreas K, Zehbe R, Kazubek M et al. Biodegradable insulin-loaded PLGA microspheres fabricated by three different emulsifcation techniques: Investigation for cartilage tissue engineering. Acta Biomat. 7, 1485-1495 (2011).
105. Jensen D, Jensen L, Koocheki S et al. Design of an inhalable dry powder formulation of DOTAP-modifed PLGA nanoparticles loaded with siRNA J. Cont. Rel. 157 141-148 (2012).
106. Acharya S, Sahoo S. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect Adv. Drug Del. Rev. 63, 170-183 (2011).
107. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modifed with monoclonal antibody. J. Cont. Rel. 120(1-2), 18-26 (2007).
108. Tahara K, Miyazaki Y, Kawashima Y, Kreuter J, Yamamoto H. Brain targetting with surface-modifed poly (D, L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration. Eur. J. Pharma. Biopharm. 77, 84-88 (2011).
109. Lai P, Hong D, Lin C, Chen L, Chen W, Chu I. Effect of mixing ceramics with a thermosensitive biodegradable hydrogel as composite graft. Composites Part B 43, 3088-3095 (2012).
110. Fan D, Rosa E, Murphy M et al. Mesoporous silicon-PLGA composite microspheres for the double controlled release of biomolecules for orthopedic tissue engineering. Advanced Functional Materials 22(2), 282-293 (2012).
111. Razak S, Sharif N, Rehman W. Biodegradable polymers and their bone applications: A review. Int. J. Basic Appl. Ssci. 12(1), 31-50 (2012).
112. Niu C, Wang Z, Lu G et al. Doxorubicin loaded superparamagnetic PLGA iron oxide multifunctional microbubbles for dual mode US/MR imaging and therapy of metastasis in lymph nodes. Biomaterials 34, 2307-2317 (2013).
113. Schleich N, Sibret P, Danhier P et al. Dual anticancer drug/super paramagnetic iron oxide loaded PLGA based nanoparticles for cancer therapy and magnetic resonance imaging. Int. J. Pharm. 447, 94-101 (2013).
114. Figueiredo M, Esenaliev R. PLGA nanoparticles for ultrasound mediated gene delivery to solid tumors. J. Drug Deliv. 2012, 1-12 (2012).
115. Sun B, Ranganathan B, Feng S. Multifunctional poly (D, L-lactide-co-glycolide)/montmorillonite nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 29, 475-486 (2008).
116. Pejcic A, Kesić L, Obradović R, Mirković D. Antibiotics in the management of periodontal disease. Scientifc Journal of the Faculty of Medicie in NIS 27(2), 85-92 (2010).
117. Jain R, Shah N, Malick A, Rhodes C. Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug Dev. Ind. Pharm. 24(8), 703-727 (1998).
118. Perugini P, Genta I, Conti B, Modena T, Pavanetto F. Periodontal delivery of iprifavone: new chitosan/PLGA flm delivery system for a lipophilic drug. Int. J. Pharm. 252, 1-9 (2003).
119. Nafea E, Massik M, Khordagui L, Marej M, Khalafallah N. Alendronate PLGA microspheres with high loading effciency for dental applications. J. Microencapsul. 24(6), 525-538 (2007).
120. Perugini P, Simeoni S, Scalia B et al. Effect of nanoparticle encapsulation on the photostability of the sunscreen agent, 2-ethylhexyl-p-methoxycinnamate. Int. J. Pharm. 246, 37-45 (2002).
121. Tsujimoto H, Hara K, Tsukada Y et al. Evaluation of the permeability of hair growing ingredient encapsulated PLGA nanospheres to hair follicles and their hair growing effects. Bioorg. Med. Chem. Lett. 17, 4771-4777 (2007).
122. Danhier F, Ansorena E, Silva J, Coco R, Breton A, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release 161, 505-522 (2012).
123. Lever M J. Cardiovascular assist. In: Biomaterials, artifcial organs and tissue engineering. Hench LL, Jones JR (Eds). Woodhead publishing limited, Cambridge, England (2005).
124. Klugherz BD, Jones PL, Cui X. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat. Biotech. 18, 1181-1184 (2000).
125. Ganaha F, Kao E Y, Wong H. Stent-based controlled release of intravascular angiostatin to limit plaque progression and in-stent restenosis. J. Vasc. Interv. Radiol. 15, 601-608 (2004).
126. Banai S, Gertz S D, Gavish L. Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. Cardiovasc. Res. 64, 165-171 (2004).
127. Kerimoglu O, Alarcin E. Poly(lactic-co-glycolic acid) based drug delivery devices for tissue engineering and regenerative medicine. Ankem Dergisi 26(2), 86-98 (2012).
128. Gadad A, Vannuruswamy G, Sharath C, Dandagi P, Mastiholimath V. Study of different properties and applications of poylactic-co-glycolic acid(PLGA) Nanotechnology 12(49), 5-23 (2012).
129. Zhu W, masaki T, Bae Y H, Rathi R, cheung A K, Kern S E. Development of a sustained-release system for perivascular delivery of dipyridamole. J. Biomed. Mater. Res. B Appl. Biomater. 77, 135-143 (2004).
130. Tomoda K, Terashima H, Suzuki K, Inagi T, Terada H, Makino K. Enhanced transdermal delivery of indomethacin using combination of PLGA nanoparticles and iontophoresis in vivo Colloids Surf. B. Biointerfaces 92, 50-54 (2012).
131. Luengo J, Weiss B, Schneider M et al. Infuence of nanoencapsulation on human skin transport of fufenamic acid. Skin Pharmacol. Physiol. 19 (4), 190-197 (2006).
132. Marimuthu M, Bennet D, Kim S. Self-assembled nanoparticles of PLGA-conjugated glucosamine as a sustained transdermal drug delivery vehicle. Polymer J. 45, 202-209 (2013).